Related Experiment Videos
Intra-arterial chemotherapy for bladder cancer
1Department of Urology, University of Tsukuba, Ibaragi Prefecture, Japan.
Cancer Chemotherapy and Pharmacology
|January 1, 1987
Summary
Intra-arterial chemotherapy using adriamycin via the inferior gluteal artery showed a 58.4% 5-year survival rate in bladder cancer patients. This method appears effective as preoperative adjuvant therapy with minimal side effects.
Area of Science:
- Oncology
- Vascular Surgery
Background:
- Bladder cancer treatment often involves radical cystectomy.
- Neoadjuvant chemotherapy aims to improve surgical outcomes.
- Intra-arterial chemotherapy offers targeted drug delivery.
Purpose of the Study:
- To evaluate the efficacy of intra-arterial adriamycin infusion chemotherapy prior to cystectomy for bladder cancer.
- To compare outcomes between superior and inferior gluteal artery infusion routes.
Main Methods:
- 32 bladder cancer patients received neoadjuvant intra-arterial adriamycin (ADM) chemotherapy.
- Catheters were inserted into either the superior or inferior gluteal artery.
- ADM was administered at 10 mg twice weekly.
Main Results:
- Inferior gluteal artery infusion in 25 patients yielded a 5-year survival rate of 58.4%.
- Superior gluteal artery infusion in 7 patients had a 14.3% 5-year survival rate.
- No recurrence was observed in patients surviving over 2 years post-cystectomy.
Conclusions:
- Inferior gluteal artery infusion chemotherapy demonstrates promising efficacy as neoadjuvant therapy for bladder cancer.
- This approach appears to have a favorable safety profile with no serious side effects.
- Treatment was ineffective for stage-T4 cases, indicating limitations.